Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate | Prostate Cancer and Prostatic Diseases
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial - European Urology
ASCO GU 2019: The CHEIRON Study - A Multicentric Phase II Randomized Trial of Docetaxel Plus Enzalutamide versus Docetaxel as First-Line Chemotherapy for Patients with mCRPC
A-C) Overall survival of 68 patients with metastesis castration... | Download Scientific Diagram
Genomic correlates of clinical outcome in advanced prostate cancer | PNAS
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
PREVAIL Trial Efficacy and Safety | XTANDI® (enzalutamide) Safety Info
Overall Survival (OS) for mCRPC patients treated with docetaxel for a... | Download Scientific Diagram
a) Progression free and b) overall survival probability of patients... | Download Scientific Diagram
Overall survival and second primary malignancies in men with metastatic prostate cancer
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer - Annals of Oncology
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors - European Urology
Recent Advances in the Management of Metastatic Prostate Cancer | JCO Oncology Practice
Advances in Treating mCRPC: Focus on Immunotherapy
Overall survival and second primary malignancies in men with metastatic prostate cancer
The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study - ScienceDirect
The Place of Targeted Alpha Therapy Optimizing Overall Survival in mCRPC Today and in the Future | ESMO
Progression-free survival of mCRPC patients treated with AAP | Download Scientific Diagram
Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial - Annals of Oncology
Visceral Metastases and Prostate Cancer Treatment: 'Die Hard,' 'Tough Neighborhoods,' or 'Evil Humors'?
ASCO GU 2020: Treatment of Chemotherapy-Naïve mCRPC Using Abiraterone Acetate with or without Cabazitaxel
Overall survival. mCRPC metastatic castration-resistant protate cancer.... | Download Scientific Diagram
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study | In Vivo
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases
